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WTP threshold, certolizumab may be the most cost-effective agent for the treatment 
of rheumatoid arthritis compared to all other TNF-alpha inhibitors.
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BACKGROUND: Biological therapies including inﬂiximab, etanercept, adalimumab 
and abatacept are options for rheumatoid arthritis (RA) patients who had an inade-
quate response to Disease-Modifying Anti-Rheumatic Drugs (DMARDs), such as 
methotrexate (MTX). OBJECTIVES: To determine the cost-effectiveness of abatacept 
compared to other biologics in the treatment of moderate-to-severe active RA in 
patients with inadequate response to MTX in Canada. METHODS: An existing US-
based cost-effectiveness model was adapted to the Canadian setting. The techniques 
of dynamic simulation were employed to estimate the impact of abatacept and other 
biologics on functional disability (expressed in patients’ Health Assessment Question-
naire (HAQ) scores) and clinical and economic outcomes. The model focuses on a 
hypothetical cohort of patients, simulating their disability quarterly over 1, 5, 10 years 
and lifetime. First-order simulation was conducted to gauge the inﬂuence of individual 
input parameters. Second-order Monte Carlo simulation was performed to examine 
the overall effect of uncertainty in the model. Efﬁcacy data were based on a separate 
meta-analysis. The perspective adopted was that of a provincial ministry of health. 
Utility data were obtained from a study that mapped Health Utility Index values on 
a Canadian RA population. Costs (2009 CAD) and outcomes were discounted at 5% 
annually. RESULTS: Abatacept has a cost-effectiveness ratio of approximately 
$93,000 per QALY gained vs. MTX, comparable with those of etanercept ($96,000) 
and adalimumab ($112,000) and much lower than that of inﬂiximab ($171,000). At 
willingness-to-pay between $80,000 and $97,000, abatacept is the most cost-effective 
option. Results were most sensitive to the assumption of the threshold for clinically 
meaningful HAQ improvement at 6-month and applied time horizon. CONCLU-
SIONS: Determination of an appropriate biological therapy in RA depends on multiple 
factors including economic value. Abatacept offers a valuable therapeutic option for 
the treatment of moderate-to-severe active RA in patients with inadequate response 
to one or more DMARD therapies.
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OBJECTIVES: Duloxetine, a serotonin and norepinephrine reuptake inhibitor, has 
been approved for the treatment of both major depressive disorder (MDD) and certain 
chronic pain-related diseases (CPD). This study examined the association between 
adherence to duloxetine and hospital utilization among MDD patients with CPD. 
METHODS: This is a retrospective cohort study analyzing data from the MarketScan 
commercial databases. Patients were included in the analyses if they used duloxetine 
during the index period of July 1, 2006-June 30, 2007 and had no record of duloxetine 
use during a 3-month washout period. Inclusion criteria required MDD diagnosis and 
at least one CPD of interest (ﬁbromyalgia, diabetes with neurological manifestations, 
low back pain, headache, and osteoarthritis). Patients were followed up 12 months 
after index date. Adherence was deﬁned as medication possession ratio (MPR) of 80% 
or higher. Hospital utilization included emergency room visits and hospitalizations. 
Psychiatric hospitalizations were based on principal diagnosis codes for admissions. 
Logistic regression and negative binomial regression models were used to adjust for 
patient characteristics. RESULTS: Compared to those with MPR < 80% (n = 2,988), 
patients adherent to duloxetine (n = 2,589) had fewer emergency room visits (1.51 vs. 
2.07; p < 0.0001), lower likelihood of emergency room visit (36.85% vs. 41.57%; p 
= 0.0003), fewer all-cause hospitalizations (0.34 vs. 0.46; p < 0.0001), fewer psychi-
atric hospitalizations (0.10 vs. 0.15; p < 0.0001), fewer all-cause hospitalization days 
(1.46 vs. 2.43; p < 0.0001), fewer psychiatric hospitalization days (0.53 vs. 1.04; p = 
0.0001), lower likelihood of hospitalization for any cause (20.97% vs. 25.07%; 
p = 0.0003) and lower likelihood of psychiatric hospitalization (6.80% vs. 8.97%; 
p = 0.0028). These differences were essentially the same after adjusting for patient 
characteristics. CONCLUSIONS: Adherence to duloxetine was associated with lower 
hospital utilization among MDD patients with CPD, suggesting the importance of 
improving patient adherence to duloxetine. Future studies should examine whether 
the lower hospital utilization associated with duloxetine adherence translates to lower 
costs.
MUSCULAR-SKELETAL DISORDERS – Patient-Reported Outcomes Studies
PMS31
AN EVENT-LEVEL ANALYSIS OF PRESCRIPTION REFILL INTERVALS 
FOR ADALIMUMAB AND ETANERCEPT IN THE TREATMENT OF 
RHEUMATOID ARTHRITIS
Rizzo J1, Gunnarsson C2, Fang H3, Carter C4, Bolge S4, McKenzie RS4
1Stony Brook University, Stony Brook, NY, USA, 2S2 Statistical Solutions Inc, Cincinnati, OH, 
USA, 3U of Colorado at Boulder, Aurora, CO, USA, 4Centocor Ortho Biotech Services, 
LLC, Horsham, PA, USA
OBJECTIVES: To assess differences in rates of shorter, longer, and on-time prescrip-
tion reﬁll intervals for adalimumab and etanercept in rheumatoid arthritis (RA) and 
to identify factors associated with rates of longer prescription reﬁll intervals. 
METHODS: An event-level analysis was conducted using medical/pharmacy claims 
from a database of 98 managed care plans. Inclusion criteria included index tumor 
necrosis factor inhibitor (anti-TNF) started January 2004-December 2007, patient age 
≥18, 2 RA diagnosis codes (ICD-9 code 714.xx), and 365 days of index anti-TNF 
treatment. Patients with selected other inﬂammatory conditions or evidence of anti-
TNFs during 6 months prior to index date or abatacept or rituximab while on index 
anti-TNF were excluded. Prescription reﬁll intervals were assessed by comparing the 
observed time between dates of prescription claims with recommended dosing fre-
quency in prescribing information (i.e., adalimumab = 14 days, etanercept = 7 days). 
Observed reﬁlls within seven days of the recommended dosing frequency were con-
sidered “on time”; intervals greater than seven days “longer”; and less than seven days 
“shorter”. Multivariable logistic regression analyses were performed to examine deter-
minants of longer reﬁll intervals. RESULTS: There were 26,103 prescription reﬁll 
events for adalimumab (N = 1,279 patients), and 48,859 for etanercept (N = 2,277 
patients). Rates of shorter reﬁll intervals were low: 3.7% for adalimumab and 3.5% 
for etanercept. Longer and on-time reﬁll interval rates were comparable for adalim-
umab (27.4% and 68.9%) and etanercept (29.5% and 67.0%), respectively. Regres-
sion analyses revealed etanercept longer intervals increased with duration of use (p < 
0.01), female gender (p < 0.01), and lack of insurance (p < 0.01), but decreased with 
older age (p < 0.01). A similar pattern emerged for adalimumab. CONCLUSIONS: 
More than one in four of all adalimumab and etanercept prescription reﬁll events in 
RA had longer reﬁll intervals than recommended. Further research is warranted assess-
ing the clinical and economic consequences of delays in prescription reﬁlls, which may 
be suggestive of under-dosing.
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OBJECTIVES: To evaluate switching, discontinuation, and persistence among patients 
with RA receiving anti-TNFs. METHODS: This was a retrospective cohort study of 
RA patients, in a large managed care database, using their ﬁrst anti-TNF January 1, 
2005 -June 30, 2006. Patients were required to have ≥30 months of continuous plan 
eligibility: 6 months prior to and 24 months following their index anti-TNF date, and 
no evidence of pre-index biologic use. For patients with index adalimumab (ADA) or 
etanercept (ETA), a gap in days’ supply exceeding 60 days (i.e., no ﬁlls between 
prescription ﬁll dates and prescription ﬁll date + days supply + 60) indicated discon-
tinuation. For patients with index inﬂiximab (IFX), a gap in medical claims for infu-
sions >8 weeks + 60 days indicated discontinuation. Switching was deﬁned as use of 
a new biologic post-index. Persistence was deﬁned as continuous use of index anti-
TNF without discontinuation or switching. Differences in switching, discontinuation, 
and persistence rates were evaluated.RESULTS: A total of 1780 patients were ana-
lyzed: ADA = 601 (33.8%); ETA = 785 (44.1%); IFX = 394 (22.1%). Over three-
quarters (77%) were female; mean age was 50.1 years. IFX patients were older and 
had a higher Charlson-Quan comorbidity score than ADA or ETA patients. Each 
treatment group experienced switching (ADA = 13.1%, ETA = 11%, IFX = 13.5%). 
The IFX group had the lowest rate of discontinuation (37.6%) and greatest persistence 
(49%) compared to ADA (57.2% discontinuation, 29.6% persistence; p < 0.0001 for 
both) or ETA (57.5% discontinuation, 31.6% persistence; p < 0.0001 for both). 
CONCLUSIONS: These results indicate that among RA patients receiving anti-TNFs, 
the portion that switch does not vary by treatment in the 2 years following start of 
therapy. However, differences in discontinuation and persistence were noted. Studies 
are needed to investigate reasons for and impact of discontinuation and persistence 
on clinical and economic outcomes.
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OBJECTIVES: To examine attitudes and satisfaction with decision-making among 
psoriatic arthritis (PA) patients, comparing them with cutaneous psoriasis (CP) 
patients. A further aim was to analyse factors associated with patients preferring an 
active participation and patient satisfaction. METHODS: A questionnaire was self-
completed after a routine medical visit by a consecutive sample of 231 psoriasis 
patients, including 33 PA patients. The questionnaire was based on previously pub-
